RxDoctor Payments Data

Ignacio Pita Garcia, MD

Clinical Neurophysiology · Guaynabo, PRNPI 1447286679

Payments from drug & device makers

$19,420in general payments, 2019–2025

Across 89 payments — averaging $218.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$16K
  • Medtronic$2K
  • Jazz Pharmaceuticals Inc.$315
  • Greenwich Biosciences, Inc.$160
  • Sunovion Pharmaceuticals Inc.$153
  • Neurelis, Inc.$133
  • plus $721 from 13 others

What the payments were for

  • Consulting fees$1,4708%
  • Speaking & faculty fees$14,00072%
  • Travel & lodging$1,0515%
  • Food & beverage$2,89915%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$29,947
Medicare patients
65
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)186$989,516
KeppraLevetiracetam349$533,189
VimpatLacosamide281$390,760
TopamaxTopiramate182$276,702
FinteplaFenfluramine Hcl14$227,605
LamictalLamotrigine179$171,781
BanzelRufinamide56$148,334
Keppra XrLevetiracetam64$137,378
BriviactBrivaracetam85$121,974
TrileptalOxcarbazepine97$119,662
OnfiClobazam46$110,624
Clobazam277$94,568
FycompaPerampanel35$90,855
AptiomEslicarbazepine Acetate52$80,917
DepakoteDivalproex Sodium74$72,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Fintepla, Briviact$16,375$740,340380 claims
Eisai Inc.Banzel, Fycompa$27$239,18991 claims
Sunovion Pharmaceuticals Inc.Aptiom$153$80,91752 claims
Johnson & JohnsonRisperdal$93$3,73011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Guaynabo

Where these figures come from

Is this you, or does something look wrong? →